Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749516 | 0.81 | NOTUM (0.40) | RPS6KB1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1750584 | 0.80 | CHRM4 (0.41) | GAACHRM4RPS6KB1USP30LMNA | |
| SCHEMBL1749741 | 0.78 | RPS6KB1 (0.40) | RPS6KB1USP30MEN1ALDH1A1LMNA | |
| SCHEMBL1749472 | 0.78 | RPS6KB1 (0.48) | RPS6KB1ALDH1A1MAPTNOTUMTDP1 | |
| SCHEMBL6792106 | 0.76 | MAPT (0.42) | GAACHRM4USP30MEN1ALDH1A1 | |
| SCHEMBL1749817 | 0.75 | GAA (0.41) | GAARPS6KB1USP30NOTUMTDP1 | |
| SCHEMBL1748829 | 0.73 | DRD2 (0.45) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL1749834 | 0.73 | P2RX7 (0.46) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL1749401 | 0.73 | MAPT (0.46) | GAARPS6KB1MEN1ALDH1A1LMNA | |
| SCHEMBL1749277 | 0.72 | CHRM4 (0.40) | GAACHRM4RPS6KB1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | GAA 1379/4885CHRM4 2150/4885RPS6KB1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.